John N. Allan

4.9k total citations · 1 hit paper
97 papers, 1.1k citations indexed

About

John N. Allan is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, John N. Allan has authored 97 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Genetics, 42 papers in Pathology and Forensic Medicine and 25 papers in Hematology. Recurrent topics in John N. Allan's work include Chronic Lymphocytic Leukemia Research (76 papers), Lymphoma Diagnosis and Treatment (41 papers) and Chronic Myeloid Leukemia Treatments (14 papers). John N. Allan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (76 papers), Lymphoma Diagnosis and Treatment (41 papers) and Chronic Myeloid Leukemia Treatments (14 papers). John N. Allan collaborates with scholars based in United States, Italy and Australia. John N. Allan's co-authors include Richard R. Furman, Thomas J. Kipps, Mónica L. Guzmán, William G. Wierda, James P. Dean, Paolo Ghia, Tanya Siddiqi, Constantine S. Tam, Cathy Zhou and Silvia Deaglio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

John N. Allan

82 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John N. Allan United States	21	803	708	333	319	286	97	1.1k
Kathryn Humphrey United Kingdom	16	1.0k 1.3×	920 1.3×	433 1.3×	369 1.2×	320 1.1×	52	1.4k
Eugen Tausch Germany	18	686 0.9×	536 0.8×	188 0.6×	309 1.0×	180 0.6×	72	1.0k
Timothy J. Murphy United States	9	778 1.0×	799 1.1×	310 0.9×	399 1.3×	158 0.6×	19	1.2k
Olga Samoilova Russia	9	574 0.7×	634 0.9×	388 1.2×	179 0.6×	254 0.9×	20	912
Marwan Kwok United Kingdom	10	522 0.7×	422 0.6×	288 0.9×	277 0.9×	122 0.4×	15	881
Cynthia A. Sirard United States	14	464 0.6×	444 0.6×	376 1.1×	473 1.5×	110 0.4×	44	1.0k
Ruth de Tute United Kingdom	11	513 0.6×	373 0.5×	225 0.7×	309 1.0×	379 1.3×	28	871
Sanne H. Tonino Netherlands	18	521 0.6×	467 0.7×	513 1.5×	375 1.2×	107 0.4×	48	987
Andrew Greaves United States	11	1.1k 1.3×	780 1.1×	129 0.4×	623 2.0×	140 0.5×	23	1.2k
Yvona Brychtová Czechia	19	704 0.9×	450 0.6×	294 0.9×	385 1.2×	221 0.8×	71	1.2k

Countries citing papers authored by John N. Allan

Since Specialization

Citations

This map shows the geographic impact of John N. Allan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John N. Allan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John N. Allan more than expected).

Fields of papers citing papers by John N. Allan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John N. Allan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John N. Allan. The network helps show where John N. Allan may publish in the future.

Co-authorship network of co-authors of John N. Allan

This figure shows the co-authorship network connecting the top 25 collaborators of John N. Allan. A scholar is included among the top collaborators of John N. Allan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John N. Allan. John N. Allan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kang, Tae Sun, Qi Gao, Liming Bao, et al.. (2025). Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi. Cell Genomics. 6(1). 101036–101036.

Castillo, Jorge J., John N. Allan, Tanya Siddiqi, et al.. (2025). Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia. Blood Advances. 9(19). 4842–4847.

Thompson, Meghan C., Ricardo Parrondo, Anna Maria Frustaci, et al.. (2024). Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study. Blood. 144(Supplement 1). 885–885. 14 indexed citations

Ruan, Jia, David A. Bond, Bijal Shah, et al.. (2024). MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses. Blood. 144(Supplement 1). 746–746. 2 indexed citations

Lasica, Masa, Sikander Ailawadhi, Chengcheng Fu, et al.. (2024). Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 42(16_suppl). 7078–7078. 1 indexed citations

Kittai, Adam S., John N. Allan, Jack Roos, et al.. (2024). An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Advances. 8(11). 2861–2869. 8 indexed citations

Wierda, William G., Ryan Jacobs, Paul M. Barr, et al.. (2024). CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Clinical Lymphoma Myeloma & Leukemia. 24. S342–S342.

Allan, John N., et al.. (2024). CLL-481 Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review. Clinical Lymphoma Myeloma & Leukemia. 24. S356–S356.

Wierda, William G., Ryan Jacobs, Paul M. Barr, et al.. (2024). Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Clinical Lymphoma Myeloma & Leukemia. 24. S179–S179.

10.

Ghia, Paolo, John N. Allan, Tanya Siddiqi, et al.. (2023). FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY. Hematological Oncology. 41(S2). 238–239. 1 indexed citations

11.

Allan, John N., Adam S. Kittai, Jack Roos, et al.. (2023). A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia. Blood. 142(Supplement 1). 6563–6563.

12.

Jain, Nitin, Lisa J. Croner, John N. Allan, et al.. (2023). Absence of BTK , BCL2 , and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clinical Cancer Research. 30(3). 498–505. 20 indexed citations

13.

Geyer, Julia T., Amy Chadburn, Ethel Cesarman, et al.. (2023). Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib. Pathobiology. 90(5). 356–364. 2 indexed citations

14.

Barr, Paul M., Alessandra Tedeschi, William G. Wierda, et al.. (2022). Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts. Clinical Cancer Research. 28(20). 4385–4391. 6 indexed citations

15.

Tam, Constantine S., John N. Allan, Tanya Siddiqi, et al.. (2022). Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 139(22). 3278–3289. 124 indexed citations breakdown →

16.

Rogers, Kerry A., Philip A. Thompson, John N. Allan, et al.. (2021). Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 106(9). 2364–2373. 76 indexed citations

17.

Ujjani, Chaitra S., Anthony R. Mato, Brian T. Hill, et al.. (2020). <p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. SHILAP Revista de lepidopterología. Volume 10. 1–5. 6 indexed citations

18.

Tam, Constantine S., Tanya Siddiqi, John N. Allan, et al.. (2019). Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood. 134(Supplement_1). 35–35. 31 indexed citations

19.

Vaisitti, Tiziana, Esteban Braggio, John N. Allan, et al.. (2018). Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. Cancer Research. 78(13). 3413–3420. 33 indexed citations

20.

Allan, John N. & Richard R. Furman. (2017). Optimal management of the young patient CLL patient. Best Practice & Research Clinical Haematology. 31(1). 73–82. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact